Investigating the Effects of Zingiber officinale plate on Growth Pains in Pediatrics

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250203064631N1

Enrollment

Registered

2025-06-02

Start date

2025-06-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growing pains. Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive tablets containing ginger extract (hydroalcoholic extract equivalent to 250 mg of ginger rhizome powder, standardize

Eligibility

Sex/Gender

All

Age

3 Years to 12 Years

Inclusion criteria

Inclusion criteria: Age 3 to 12 years Clinical diagnosis of growing pains by a specialist physician after ruling out organic causes of pain. Patient and guardian consent to the study and completion of the informed consent form by the patient's legal guardian.

Exclusion criteria

Exclusion criteria: Having underlying diseases that may cause similar pain. Regular use of anti-inflammatory or analgesic medications. Known allergy to ginger.

Design outcomes

Primary

Measure	Time frame
Symptoms associated with pain. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to growing pains.;Duration of pain. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to growing pains.;Sequence of pains. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to growing pains.;Wake-up sequence. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to growing pains.;Possibility of falling asleep due to growing pains. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to gr	—

Measure

Time frame

Symptoms associated with pain. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to growing pains.;Duration of pain. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to growing pains.;Sequence of pains. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to growing pains.;Wake-up sequence. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to growing pains.;Possibility of falling asleep due to growing pains. Timepoint: At the beginning of the study and after three months of receiving the drug. Method of measurement: The Visual Analogue Scale (VAS) of pain and the Tool for Children’s Growing Pains complement the checklist of symptoms associated with pain, including duration of pain, sequence of pains, sequence of awakenings from sleep or sleep disturbance due to gr

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdolreza Malek

Mashhad University of Medical Sciences

malekar@mums.ac.ir+98 915 313 1417

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026